Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...

PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company” or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic ...

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Q1 2025 Results Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsSteve Halper - Investor RelationsBob Leasure ...

NeuroOne Medical Technologies Corporation ( NASDAQ: NMTC) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET ...

2025 FIRST-QUARTER ACTIVITY B2C - sales of cars to private ... despite an unfavourable calendar effect in 2025 compared to 2024, exceptional circumstances in Spain, and the extraordinary dynamism ...

Palatin Technologies, Inc. (AMEX: PTN) Q2 2025 Earnings Call Transcript February 13, 2025 ...

New and Renewal Leases Signed: 486,000 square feet in the fourth quarter and 1,306,000 square feet for the full year 2024 in our wholly-owned portfolio and including leasing within our unconsolidated ...

This Artificial Intelligence (AI) Stock Has Jumped 30% Already in 2025. It Could Jump Another 32%, According to Wall Street.

Q2 2025 Earnings Call Transcript February 12, 2025 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.26, ...